ALX 1
Alternative Names: ALX-1; carbon-bound diazeniumdiolate; MD-3Latest Information Update: 22 Jan 2024
At a glance
- Originator Vast Therapeutics
- Class Antibacterials; Small molecules
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Bronchiectasis; Nontuberculous mycobacterium infections
Most Recent Events
- 17 Jan 2024 Pharmacodynamics data from preclinical trial in Nontuberculous mycobacterium infections released by Vast Therapeutics
- 11 Jul 2022 Vast Therapeutics has patents pending for nitric oxide related materials and uses (Vast Therapeutics website, July 2022)
- 11 Jul 2022 Vast Therapeutics has worldwide patent protection for multiple nitric oxide-releasing compounds and their pharmaceutical formulations (Vast Therapeutics website, July 2022)